HFCAS OpenIR

Browse/Search Results:  1-10 of 26 Help

Selected(0)Clear Items/Page:    Sort:
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements 期刊论文
NPJ PRECISION ONCOLOGY, 2022, 卷号: 6
Authors:  Zhang, Yongchang;  Huang, Zhe;  Zeng, Liang;  Zhang, Xiangyu;  Li, Yizhi;  Xu, Qinqin;  Yang, Haiyan;  Lizaso, Analyn;  Xu, Chunwei;  Liu, Jun;  Wang, Wenxian;  Song, Zhengbo;  Ou, Sai-Hong Ignatius;  Yang, Nong
Favorite  |  View/Download:5/0  |  Submit date:2022/05/05
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis 期刊论文
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
Authors:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng;  Zou, Dehui;  Li, Wei;  Yang, Haiyan;  Liu, Ting;  Wang, Quanshun;  Lv, Fangfang;  Guo, Haiyi;  Zhao, Xia;  Wang, Dan;  Zhang, Pei;  Wang, Yidi;  Wang, Lei;  Liu, Tengfei;  Zhang, Yun;  Shen, Zhirong;  Huang, Jane;  Zhu, Jun
Favorite  |  View/Download:4/0  |  Submit date:2022/05/05
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文
BMC CANCER, 2022, 卷号: 22
Authors:  Chen, Xi;  Kong, Haiying;  Luo, Linxiang;  Han, Shuiyun;  Lei, Tao;  Yu, Haifeng;  Guo, Na;  Li, Cong;  Peng, Shuailing;  Dong, Xiaowu;  Yang, Haiyan;  Wu, Meijuan
Favorite  |  View/Download:10/0  |  Submit date:2022/02/14
Hodgkin lymphoma  PD-1 inhibitor  PD-L1 inhibitor  PD-L2  Molecular phenotype  Tumor microenvironment  
If small molecules immunotherapy comes, can the prime be far behind? 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 卷号: 218
Authors:  Zhang, Jingyu;  Zhang, Yu;  Qu, Bingxue;  Yang, Haiyan;  Hu, Shengquan;  Dong, Xiaowu
Favorite  |  View/Download:10/0  |  Submit date:2021/06/15
Cancer immunotherapy  Small molecule inhibitors  Combination therapy  Tumor microenvironment  
Combination of sintilimab, anlotinib and pegaspargase "sandwich" with radiotherapy in localized natural killer/T cell lymphoma: A multicenter, phase 2 study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
Authors:  Li, Zhiming;  Sun, Peng;  Wang, Yu;  Yang, Hang;  Li, Yajun;  Zhou, Hui;  Yang, Haiyan;  Zou, Liqun
Favorite  |  View/Download:3/0  |  Submit date:2022/01/10
Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
Authors:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng;  Zou, Dehui;  Li, Wei;  Yang, Haiyan;  Liu, Ting;  Wang, Quanshun;  Lv, Fangfang;  Guo, Haiyi;  Yang, Liudi;  Huang, Jane;  Novotny, William F.;  Wang, Yidi;  Zhu, Jun
Favorite  |  View/Download:8/0  |  Submit date:2022/01/10
Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10
Authors:  Yu, Haifeng;  Kong, Haiying;  Li, Cong;  Dong, Xiaowu;  Wu, Yizhe;  Zhuang, Yuxin;  Han, Shuiyun;  Lei, Tao;  Yang, Haiyan
Favorite  |  View/Download:13/0  |  Submit date:2021/08/31
Primary central nervous system lymphoma ( PCNSL)  Bruton's tyrosine kinase (BTK)  ibrutinib  zanubrutinib  tirabrutinib  
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China 期刊论文
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021
Authors:  Zhang, Xiangyu;  Zeng, Liang;  Li, Yizhi;  Xu, Qinqin;  Yang, Haiyan;  Lizaso, Analyn;  Mao, Xinru;  Jin, Ren'an;  Zeng, Yu;  Li, Qinglin;  Wang, Jianbo;  Li, Yang;  Zhang, Yongchang;  Yang, Nong
Favorite  |  View/Download:6/0  |  Submit date:2021/03/15
Anlotinib  Immunotherapy  Programmed death 1 inhibitor  Lung cancer  
Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities 期刊论文
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2021, 卷号: 21
Authors:  Huang, Feng;  Tian, Tian;  Wu, Yizhe;  Che, Jinxin;  Yang, Haiyan;  Dong, Xiaowu
Favorite  |  View/Download:7/0  |  Submit date:2021/06/15
Isocitrate dehydrogenase 2  IDH2  mutant  inhibitors  structure-activity relationship  blood cance  
Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2020, 卷号: 9
Authors:  Li, Cong;  Lu, Fangxiao;  Lei, Tao;  Yu, Haifeng;  Yang, Haiyan
Favorite  |  View/Download:5/0  |  Submit date:2020/11/30
B-cell lymphoma  chemotherapy  interstitial pneumonia (IP)  risk factor  rituximab